Loading
Life sciences · Journal article
Journal of Gastrointestinal and Liver Diseases · September 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pancreatogenic diabetes mellitus (type 3c diabetes, T3cDM) is a distinct form of diabetes resulting from primary pancreatic disorders, most commonly chronic pancreatitis. It involves both - endocrine and exocrine dysfunction, leading to unstable glycemia with frequent hypo-and hyperglycemia. The condition is often underdiagnosed despite its notable prevalence in patients with pancreatic disease, including malignancy and post-surgical states. Clinically, it overlaps with type 1 and type 2 diabetes but is distinguished by malabsorption and weight loss. Diagnosis requires standard glycemic criteria alongside evidence of pancreatic pathology and exclusion of other diabetes types. Management combines lifestyle measures, pancreatic enzyme replacement, and primarily insulin therapy, with metformin in selected cases. Early recognition is crucial due to its association with pancreatic cancer and increased risk of microvascular complications.